Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target boosted by Jefferies Financial Group from $36.00 to $42.00 in a research note released on Monday, Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock. DYN has been the topic of several other research reports. Morgan Stanley assumed coverage on Dyne […]